Pancreatic Carcinoma — Trials

Pancreatic Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,381 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 488
Recruiting: 282
Ph III recruiting: 29
Growth YoY: +31.5%
Industry share: 36%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (201)

clinicaltrialsPublishedShowing 1–38 of 38 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06608927	Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma(PRISM-1)	active not recruiting	Phase 3	610	Arcus Biosciences, Inc.INDUSTRY	13	Sep 29, 2026	clinicaltrials
NCT07621718	Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )(RASolute 305)	recruiting	Phase 3	670	Revolution Medicines, Inc.